englishEn

Business

Hemofarm is a company that bases its growth and development on a long-term strategy.

Hemofarm is a company focused on the production of quality, affordable and safe medicinal products.

The business priorities of the company are reflected in its continuous supply to local and foreign markets and with its ongoing commitment to the education and development of its employees as the most significant resource vital to the company’s growth.

The most significant financial indicators:

Hemofarm is the leader in the Serbian pharmaceutical market holding a 34.3% share in packs, and a 17.3% share in value.1 At the same time, it is the largest exporter of medicines from the country with a 79.1% share in total exports of pharmaceutical products.

The portfolio is focused on the most important pharmacotherapeutic groups such as products for cardiovascular diseases, antibiotics and neuropsychiatric products, which corresponds also to the epidemiological structure of the therapeutic indications.

Hemofarm’s over-the-counter products (OTC) take the leading position in the pharmaceutical market of Serbia, with a share of 16.8%.2

Hemofarm’s business imperative is the continuous improvement of its portfolio containing the latest generation of medicinal products, as well as the development of new segments, primarily in oncology.

Operation within the STADA Group opens additional possibilities for the sale of Hemofarm’s products in the highly demanding EU markets.

The Rx pharmaceutical market is conditioned by the pricing policy stipulated by the Ministry of Health and the Ministry of Trade. In that sense, the prices of medicinal products are also conditioned and officially approved values, which are determined by these two competent ministries.

poslovanje

Hemofarm was again the largest exporter of medicinal products in 2014. It was ranked among the top 10 largest exporting companies in Serbia.

1 Source: ALIMS

2 Source: IMS base for 2014

High investments as a support to growth and development of the company

(*in millions of EUR)

Intensive investment is directed at:

  • modernising manufacturing plants
  • extending manufacturing and storage capacities, as well as transfer of STADA products
  • modernising laboratories (R&D, microbiological control etc.)
  • implementation and development of SAP system at the level of Hemofarm
  • continuous improvement of employees